Podium to Practice: Chicago 2025 – GI: DESTINY-Gastric04

Podium to Practice: Chicago 2025 – GI: DESTINY-Gastric04

Podium to Practice: Chicago 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Sharlene Gill

Icon Chair Speaker

Speakers

Dr. Rachel Goodwin

Dr. Florian Lordick

Studies / Trials Discussed

LBA4002 – Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study.

Studies/trials discussed:

LBA4002 – Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study.
Tagged